Pay in 4 interest-free payments of $6.47 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Sources Eli Lilly, "Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial" (May 21, 2026) TRIUMPH-1 topline: 28.3% at 80 weeks, 30.3% at 104 weeks, 45.3% achieving 30%+ weight loss Eli Lilly, "Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials" (July 23, 2026) TRIUMPH-2 (20.8% at 12 mg, A1C up to -1.6%) and TRIUMPH-3 (22.6% at 12 mg) topline, plus the stated plan to submit a BLA to the FDA in Q1 2027 ClinicalTrials.gov NCT05929066 (TRIUMPH-1) Phase 3, status Completed, primary completion April 6, 2026 Eli Lilly Q4 2025 earnings call transcript (February 4, 2026) confirmed regulatory submission planned for 2026 Eli Lilly press releases and investor communications ClinicalTrials.gov (TRIUMPH program trial registrations) Jastreboff AM, et al
Because NRF2 activation is a key regulator of antioxidant defense mechanism, these results provided a mechanistic rationale to narrow subsequent IVM experiments using QUE and SFN
Therefore, prospective clinical and translational studies are needed to further investigate this association
So while theres no final answer yet, these studies give you a pretty clear idea of what doses to expect if retatrutide gets approved
US$ 26.25
US$ 20.46
US$ 28.17
US$ 26.96
US$ 25.30
US$ 22.44
US$ 25.04
US$ 27.22
US$ 25.03
US$ 20.97
US$ 23.29
US$ 27.41
US$ 26.04
US$ 27.33
US$ 23.31
US$ 28.93
US$ 27.96
